AIM
VYGR icon

Advantage Investment Management’s Voyager Therapeutics VYGR Stock Holding History

Advantage Investment Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$10K Hold
600
– – 0.01% 655
2019
Q2 		$16K Hold
600
– – 0.01% 581
2019
Q1 		$11K Hold
600
– – 0.01% 638
2018
Q4 		$6K Buy
600
+100
+20% +$1.28K ﹤0.01% 773
2018
Q3 		$9K Hold
500
– – 0.01% 733
2018
Q2 		$10K Hold
500
– – 0.01% 653
2018
Q1 		$9K Buy
+500
New +$10.8K ﹤0.01% 699

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Advantage Investment Management's VYGR Position: Q3 2019 in Review

Advantage Investment Management held its Voyager Therapeutics (VYGR) position steady in Q3 2019 at 600 shares worth $10K. The position accounts for 0.01% of the portfolio, ranked #655.

Advantage Investment Management first reported a position in VYGR in Q1 2018 and has held it in 7 quarters since. The position peaked at $16K in Q2 2019. 131 funds tracked by Wall St. Rank hold VYGR as of Q3 2019.

  • Advantage Investment Management held 600 shares of Voyager Therapeutics worth $10K as of Q3 2019.
  • Advantage Investment Management left its Voyager Therapeutics share count unchanged in Q3 2019.
  • Voyager Therapeutics made up 0.01% of Advantage Investment Management's portfolio in Q3 2019, its #655 holding.
  • Advantage Investment Management first reported a position in Voyager Therapeutics in Q1 2018 and has held it in 7 quarters since.
  • Advantage Investment Management's Voyager Therapeutics position peaked at $16K in Q2 2019.
  • 131 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.